Report : North America Upstream Bioprocessing Market Forecast to 2030 - Regional analysis - by Product Type (Bioreactors/Fermenters, Cell Culture, Filters, Bags and Containers, and Others), Workflow (Media Preparation, Cell Culture, and Cell Separation), Usage Type (Single-use and Multi-use), and Mode (In-house and Outsourced)
At 13.1% CAGR, North America Upstream Bioprocessing Market is Projected to be Worth US$ 10,603.38 Million by 2030, says Business Market Insights.
According to Business Market Insights' research, the North America upstream bioprocessing market was valued at US$ 3,958.62 million in 2022 and is expected to reach US$ 10,603.38 million by 2030, registering a CAGR of 13.1% from 2022 to 2030. Increasing investments in R&D in biopharmaceutical industry and technological advancements are among the critical factors attributed to the North America upstream bioprocessing market expansion.
Increasing investments in research and development (R&D) in the biopharmaceutical industry are likely to bring new trends into the upstream bioprocessing market in the coming years. In March 2020, Culture Biosciences announced securing the funds of US$ 15 million (13.4 million) in the Series A investment round, citing the backing of new and existing venture capital backers. According to Culture Biosciences, the money has been used to treble the capacity of bioreactors as well as to develop more cloud-based software monitoring and development tools for biomanufacturing research and development. The company states that this investment will help scientists manage their whole R&D workflow via software applications, hence supporting the digitization of biomanufacturing R&D.
As R&D investments continue to surge, particularly in novel biologics, advanced therapies, and personalized medicine, there is a parallel emphasis on optimizing upstream bioprocessing technologies and methodologies. This trend is leading to the development of innovative bioreactor systems, cell culture media formulations, and process automation solutions to enhance the efficiency, scalability, and productivity of biopharmaceutical production operations. Furthermore, the focus on R&D investments favors the development of cutting-edge bioprocessing platforms that cater to the evolving landscape of biopharmaceuticals, including next-generation therapeutic modalities and biosimilars. Additionally, dedicating R&D funds for bioprocessing trends such as continuous bioprocessing and advanced analytics for process monitoring is expected to reshape the future of upstream bioprocessing, driving the adoption of state-of-the-art technologies and establishing new benchmarks for process performance, quality, and regulatory compliance.
On the contrary, stringent regulatory framework hampers the growth of North America upstream bioprocessing market.
Based on product type, the North America upstream bioprocessing market is segmented into bioreactors/fermenters, cell culture, filters, bags and containers, and others. The bioreactors/fermenters segment held 35.1% market share in 2022, amassing US$ 1,390.54 million. It is projected to garner US$ 3,692.55 million by 2030 to expand at 13.0% CAGR during 2022-2030.
Based on workflow, the North America upstream bioprocessing market is segmented into media preparation, cell culture, and cell separation. The cell separation segment held 40.1% share of North America upstream bioprocessing market in 2022, amassing US$ 1,586.39 million. It is projected to garner US$ 4,438.70 million by 2030 to expand at 13.7% CAGR during 2022-2030.
By usage type, the North America upstream bioprocessing market is bifurcated into single-use and multi-use. The single-use segment held 55.2% share of North America upstream bioprocessing market in 2022, amassing US$ 2,183.60 million. It is projected to garner US$ 5,950.88 million by 2030 to expand at 13.4% CAGR during 2022-2030.
In terms of mode, the North America upstream bioprocessing market is bifurcated into In-house and outsourced. The outsourced segment held 59.3% share of North America upstream bioprocessing market in 2022, amassing US$ 2,346.30 million. It is projected to garner US$ 6,163.04 million by 2030 to expand at 12.8% CAGR during 2022-2030.
Based on country, the North America upstream bioprocessing market has been categorized into the US, Canada, and Mexico. Our regional analysis states that the US captured 83.2% share of North America upstream bioprocessing market in 2022. It was assessed at US$ 3,293.97 million in 2022 and is likely to hit US$ 8,989.60 million by 2030, exhibiting a CAGR of 13.4% during 2022-2030.
Key players operating in the North America upstream bioprocessing market are Thermo Fisher Scientific Inc, Esco Micro Pte Ltd, Sartorius AG, Danaher Corp, Getinge AB, Merck KGaA, Corning Inc, Entegris Inc, and PBS Biotech Inc, among others.
- In February 2022, Thermo Fisher Scientific in announced expansion for its Bioprocessing. The company has invested US$40 million to construct and maintain a manufacturing plant for single-use technologies in Millersburg, Pennsylvania. The expansion was a part of a multiyear, US$ 650 million investment to improve the company's capacity to produce bioprocessing in a flexible, scalable, and dependable manner.
- In January 2023, Sartorius collaborated with RoosterBio Inc to address purification challenges and establish scalable downstream manufacturing processes for exosome-based therapies. Through this collaboration, Sartorius and RoosterBio will provide best-in-class solutions and expertise for a human mesenchymal stem/stromal cell (hMSC) - based exosome production platform that delivers industry-leading yield, purity, and potency.
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@businessmarketinsights.com